Evidence map›Paper›PMID 29537702›Full record

Observational studyTransplant international : official journal of the European Society for Organ Transplantation2018

Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study.

Antoine Roux, Kimberly A Thomas, Edouard Sage, Caroline Suberbielle-Boissel, Laurence Beaumont-Azuar, Francois Parquin, Morgan Le Guen, Nicholas Harre, Abdul Monem Hamid, Elaine F Reed

Registry-linked trialOpen access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Transplant international : official journal of the European Society for Organ Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06112951 (The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06112951 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT

TypeinterventionalSponsorMedical University of ViennaRan2024 to 2027Enrolled80ConditionsAntibody-mediated Rejection, Lung Transplant RejectionArmsExtracorporeal Photopheresis
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. International Society for Heart and Lung Transplantation Scientific Statement on pulmonary antibody-mediated rejection and proposed graft, antibody, and pathology (GAP) definition.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
    Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  7. Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  8. Immune processes in the pathogenesis of chronic lung allograft dysfunction: identifying the missing pieces of the puzzle.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  9. Article
  10. Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020
    Article
  11. Apoptotic cell-based therapies for promoting transplantation tolerance.Current opinion in organ transplantation · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Antoine RouxPneumology, Adult CF Center and Lung Transplantation Department, Foch Hospital, Suresnes, France.ORCID 0000-0003-2387-0669
Kimberly A ThomasDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0001-8152-9974
Edouard SageThoracic Surgery Department, Foch Hospital, Suresnes, France.
Caroline Suberbielle-BoisselLaboratoire Régional d'Histocompatibilité, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Laurence Beaumont-AzuarPneumology, Adult CF Center and Lung Transplantation Department, Foch Hospital, Suresnes, France.
Francois ParquinThoracic Intensive Care Unit, Foch Hospital, Suresnes, France.
Morgan Le GuenUniversité Versailles Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France.
Nicholas HarreDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Abdul Monem HamidPneumology, Adult CF Center and Lung Transplantation Department, Foch Hospital, Suresnes, France.
Elaine F ReedDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Hôpital Foch · FRUniversity of California, Los Angeles · USUniversité de Versailles Saint-Quentin-en-Yvelines · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

Systems Immunolobiology of Antibiotic-Persistent MRSA InfectionU01AI124319 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2020
$10.1M
NIAID NIH HHS U01 AI124319
6 · The paper itself

Abstract

Complement-mediated allograft injury, elicited by donor-specific HLA antibodies (DSA), is a defining pathophysiological characteristic of allograft damage. We aimed to study DSA-induced complement activation as a diagnostic marker of antibody-mediated rejection (AMR) and a risk stratification tool for graft loss in the context of lung transplantation (LT). We identified 38 DSA-positive patients whose serum samples were submitted for C3d deposition testing via the C3d assay. Among these 38 patients, 15 had AMR (DSA

Indexed as

Lung TransplantationAdultCohort StudiesComplement C3dComplement Pathway, ClassicalFemaleGraft RejectionGraft SurvivalHLA AntigensHumansMaleMiddle AgedYoung AdultComplement C3dHLA Antigensantibody-mediated rejectioncomplementdonor-specific HLA antibodieslung transplant

Identifiers

PMID29537702
PMCPMC5995657
OpenAlexW2791420057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.